These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24222150)

  • 1. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
    Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
    Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
    Toyooka S; Takano T; Kosaka T; Hotta K; Matsuo K; Ichihara S; Fujiwara Y; Soh J; Otani H; Kiura K; Aoe K; Yatabe Y; Ohe Y; Mitsudomi T; Date H
    Cancer Sci; 2008 Feb; 99(2):303-8. PubMed ID: 18271929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.
    Okuma Y; Shintani Y; Sekine I; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Yamamoto N; Kawaguchi T; Miyaoka E; Yoshino I; Date H
    Clin Lung Cancer; 2024 Jun; 25(4):336-346.e2. PubMed ID: 38360497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.
    Jida M; Toyooka S; Mitsudomi T; Takano T; Matsuo K; Hotta K; Tsukuda K; Kubo T; Yamamoto H; Yamane M; Oto T; Sano Y; Kiura K; Yatabe Y; Ohe Y; Date H; Miyoshi S
    Cancer Sci; 2009 Oct; 100(10):1931-4. PubMed ID: 19650855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
    Taniguchi K; Okami J; Kodama K; Higashiyama M; Kato K
    Cancer Sci; 2008 May; 99(5):929-35. PubMed ID: 18325048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L).
    Akamatsu H; Harada H; Tokunaga S; Yoshimura N; Ikeda H; Oizumi S; Sugimoto N; Takano T; Murakami H; Nishimura Y; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2019 Jan; 20(1):e25-e27. PubMed ID: 30266586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
    Traynor AM; Schiller JH; Stabile LP; Kolesar JM; Eickhoff JC; Dacic S; Hoang T; Dubey S; Marcotte SM; Siegfried JM
    Lung Cancer; 2009 Apr; 64(1):51-9. PubMed ID: 18701186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial.
    Chen C; Liu SM; Chen Y; Ou Q; Bao H; Xu L; Zhang Y; Zhong W; Zhou Q; Yang XN; Shao Y; Wu YL; Liu SY; Li Y
    JCI Insight; 2022 Jan; 7(1):. PubMed ID: 35014626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.
    Kim J; Cho CK; Yoo HS
    Integr Cancer Ther; 2016 Dec; 15(4):467-477. PubMed ID: 27151594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
    Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
    Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification.
    Wang X; Cao J; Du W; Zhang W; Cao S
    Clin Case Rep; 2021 Jul; 9(7):e04487. PubMed ID: 34322251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.
    Wilson C; Danson SJ
    Lung Cancer (Auckl); 2010; 1():37-51. PubMed ID: 28210105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Amamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status.
    Takeda T; Sasaki T; Okamoto T; Fukuda K; Hirai T; Yamada M; Nakagawa H; Mie T; Furukawa T; Kasuga A; Ozaka M; Sasahira N
    Intern Med; 2024 Jun; ():. PubMed ID: 38897958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Outcomes in NSCLC.
    Edelman MJ
    JNCI Cancer Spectr; 2019 Sep; 3(3):pkz022. PubMed ID: 32328552
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
    Zhang WQ; Li T; Li H
    Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
    Fukui T; Sasaki J; Igawa S; Kada A; Saito TI; Kogure Y; Okamoto H; Naoki K
    BMC Cancer; 2022 Dec; 22(1):1314. PubMed ID: 36522630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.
    Teranishi S; Sugimoto C; Nagaoka S; Nagayama H; Segawa W; Miyasaka A; Hiro S; Kajita Y; Maeda C; Kobayashi N; Yamamoto M; Kudo M; Kaneko T
    Thorac Cancer; 2022 Oct; 13(19):2741-2750. PubMed ID: 36082812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with
    Igawa S; Kasajima M; Ono T; Ozawa T; Kakegawa M; Kusuhara S; Sato T; Nakahara Y; Fukui T; Yokoba M; Kubota M; Mitsufuji H; Sasaki J; Naoki K
    Cancer Manag Res; 2021; 13():8695-8705. PubMed ID: 34849025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.